Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 33Unknown 8Withdrawn 4Terminated 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 104Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 33Ovarian Neoplasms 29Small Cell Lung Carcinoma 25Squamous Cell Carcinoma of Head and Neck 24Fallopian Tube Neoplasms 18Neoplasms 17Endometrial Neoplasms 17Uterine Cervical Neoplasms 13Neoplasm Metastasis 13Head and Neck Neoplasms 13Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 10Carcinoma, Squamous Cell 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Adenocarcinoma of Lung 5Stomach Neoplasms 4Pathologic Complete Response 4

Interventions

Radiotherapy 3Nivolumab 3pembrolizumab 2Temozolomide 2Surveys and Questionnaires 2Paclitaxel 2ONC206 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Etoposide 2Cyclophosphamide 2Carboplatin 2Biopsy 2regorafenib 1pegfilgrastim 1mirdametinib 1lutetium Lu 177 dotatate 1fludarabine 1etoposide phosphate 1entrectinib 1entinostat 1elacestrant 1decitabine and cedazuridine drug combination 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1aflibercept 1abemaciclib 1Topotecan 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Central Nervous System Neoplasms × Carboplatin × Clear all
NCT06528691 2026-05-13

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2 Recruiting
52 enrolled
CNS

Glioma, Central Nervous System Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡